Guilford, Pfizer neurology deal

PFE received exclusive worldwide rights to a class of n-acetylated-alpha-linked-acidic-dipeptidase ( NAALADase) inhibitors from GLFD to treat neurodegenerative diseases. PFE will be responsible for all R&D and marketing costs of the inhibitors, which are in preclinical development. GLFD retains the right to continue to develop the NAALADase inhibitors for prostate cancer, head and spinal cord injury and drug addiction. PFE has the exclusive option to acquire future products developed by GLFD for those indications. ...